Lung Cancer, Non-Small Cell
Conditions
Keywords
Non Small Cell Lung Cancer (NSCLC), Pemetrexed,, Lapatinib (GW572016),
Brief summary
This phase II study is a single-arm, two-stage, multicentre study to determine the clinical activity of lapatinib in combination with pemetrexed in patients with Non-Small Cell Lung Cancer (NSCLC) who have received one prior cytotoxic chemotherapy regimen. There will be a short safety run in portion of the study to determine the optimal treatment regimen (OTR) for the combination, since these two drugs have not previously been used together. Approximately 27 patients will be enrolled into the first stage of the study and if sufficient responses are seen an additional 27 patients will be enrolled into the second stage giving an overall evaluable patient number of 54. Patients will be treated with pemetrexed plus lapatinib at the determined OTR to disease progression, death or withdrawal from the study treatment for any reason. Safety and efficacy assessments will be performed on all patients at 6-week intervals, as well as at the end of treatment. Patients withdrawn from study treatment with stable disease will be assessed every 6 weeks until progression. Thereafter, patients will be followed for survival at approximately 12-week intervals until death or to a maximum of 5 years after last patient is enrolled, whichever comes first.
Interventions
DRUGLapatinib
Lapatinib was administered once daily orally. Patients will begin treatment at Dose Level 0, using a lower dose of pemetrexed, 400mg (approved dose is 500mg). Absent a DLT or need for treatment delay in cycle 1, Dose level 0 or 1, patients may be dose escalated to dose level 1 or 2, respectively in cycle 2.
DRUGPemetrexed
Pemetrexed is administered intravenously on a 21 day schedule. Two dose levels are used in the dose escalation: 400 and 500 mg.
Sponsors
GlaxoSmithKline
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed informed consent; * Patients must be 18 years old; * Subjects must have stage IIIB or IV NSCLC . * Recurrent or persistent NSCLC following one previous line of cytotoxic chemotherapy. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2; * Life expectancy of 12 weeks; * Have adequate organ function baseline laboratory values for inclusion;
Exclusion criteria
* History of other malignancy. Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible; * Known history of or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis except for individuals who have previously treated CNS metastases, are asymptomatic, and have had no requirement for steroids or antiseizure medication for = 3 months prior to study enrollment. * Peripheral neuropathy of grade 3 or higher; * Concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, and tumor embolization). * Prior exposure to pemetrexed or an EGFR inhibitor in combination with 5-FU or a 5FU prodrug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OTR of the combination of lapatinib and pemetrexed | — |
Secondary
| Measure | Time frame |
|---|---|
| anti-tumour activity of lapatinib in terms of overall response rate | — |
| anti-tumour activity of lapatinib in terms of duration of response, time to response, time to progression, overall survival | — |
Countries
Germany, Italy, Poland, United Kingdom
Outcome results
None listed